IFP Advisors Inc Has $13.36 Million Holdings in Pfizer Inc. (PFE)

IFP Advisors Inc trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.8% in the third quarter, HoldingsChannel.com reports. The fund owned 374,126 shares of the biopharmaceutical company’s stock after selling 3,172 shares during the period. IFP Advisors Inc’s holdings in Pfizer were worth $13,356,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Canada Pension Plan Investment Board raised its position in shares of Pfizer by 1.0% during the 3rd quarter. Canada Pension Plan Investment Board now owns 10,818,226 shares of the biopharmaceutical company’s stock worth $386,211,000 after purchasing an additional 104,600 shares during the last quarter. Longview Partners Guernsey LTD raised its position in shares of Pfizer by 32.0% during the 3rd quarter. Longview Partners Guernsey LTD now owns 24,369,672 shares of the biopharmaceutical company’s stock worth $869,997,000 after purchasing an additional 5,901,100 shares during the last quarter. Brightworth acquired a new position in shares of Pfizer during the 3rd quarter worth approximately $340,000. Sippican Capital Advisors raised its position in shares of Pfizer by 21.4% during the 3rd quarter. Sippican Capital Advisors now owns 47,874 shares of the biopharmaceutical company’s stock worth $1,709,000 after purchasing an additional 8,435 shares during the last quarter. Finally, Accredited Investors Inc. raised its position in shares of Pfizer by 58.8% during the 3rd quarter. Accredited Investors Inc. now owns 36,106 shares of the biopharmaceutical company’s stock worth $1,289,000 after purchasing an additional 13,368 shares during the last quarter. Institutional investors own 69.74% of the company’s stock.

In other news, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the sale, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the sale, the insider now directly owns 117,432 shares of the company’s stock, valued at $4,145,349.60. The disclosure for this sale can be found here. Insiders sold a total of 29,450 shares of company stock valued at $1,065,220 over the last quarter. 0.06% of the stock is currently owned by insiders.

Several research analysts recently issued reports on the company. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Monday. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price objective for the company in a research report on Monday. Nord/LB restated a “neutral” rating on shares of Pfizer in a research report on Tuesday, January 2nd. Morgan Stanley set a $41.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, Jefferies Group set a $38.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $38.83.

Pfizer Inc. (NYSE:PFE) opened at $36.41 on Wednesday. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $217,030.00, a price-to-earnings ratio of 22.34, a price-to-earnings-growth ratio of 2.46 and a beta of 1.01. Pfizer Inc. has a twelve month low of $30.90 and a twelve month high of $37.35.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. Pfizer’s revenue was up .9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.61 EPS. equities research analysts anticipate that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.

Pfizer announced that its Board of Directors has initiated a stock buyback plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be issued a $0.34 dividend. The ex-dividend date of this dividend is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.74%. Pfizer’s payout ratio is 78.53%.

COPYRIGHT VIOLATION NOTICE: “IFP Advisors Inc Has $13.36 Million Holdings in Pfizer Inc. (PFE)” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.com-unik.info/2018/01/10/ifp-advisors-inc-has-13-36-million-holdings-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit